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OBJECTIVE—MicroRNAs are short, noncoding RNAs that reg-
ulate gene expression. We hypothesized that the phosphatidyl-
inositol 3-kinase (PI 3-kinase) cascade known to be important in
-cell physiology could be regulated by microRNAs. Here, we
focused on the pancreas-speciﬁc miR-375 as a potential regulator
of its predicted target 3-phosphoinositide–dependent protein
kinase-1 (PDK1), and we analyzed its implication in the response
of insulin-producing cells to elevation of glucose levels.
RESEARCH DESIGN AND METHODS—We used insulin-
oma-1E cells to analyze the effects of miR-375 on PDK1 protein
level and downstream signaling using Western blotting, glucose-
induced insulin gene expression using quantitative RT-PCR, and
DNA synthesis by measuring thymidine incorporation. Moreover,
we analyzed the effect of glucose on miR-375 expression in both
INS-1E cells and primary rat islets. Finally, miR-375 expression in
isolated islets was analyzed in diabetic Goto-Kakizaki (GK) rats.
RESULTS—We found that miR-375 directly targets PDK1 and
reduces its protein level, resulting in decreased glucose-stimula-
tory action on insulin gene expression and DNA synthesis.
Furthermore, glucose leads to a decrease in miR-375 precursor
level and a concomitant increase in PDK1 protein. Importantly,
regulation of miR-375 expression by glucose occurs in primary
rat islets as well. Finally, miR-375 expression was found to be
decreased in fed diabetic GK rat islets.
CONCLUSIONS—Our ﬁndings provide evidence for a role of a
pancreatic-speciﬁc microRNA, miR-375, in the regulation of
PDK1, a key molecule in PI 3-kinase signaling in pancreatic
-cells. The effects of glucose on miR-375 are compatible with
the idea that miR-375 is involved in glucose regulation of insulin
gene expression and -cell growth. Diabetes 57:2708–2717,
2008
T
ype 2 diabetes currently affects 170 million
people worldwide (1). The disease is character-
ized by an inability of the functional -cell mass
to meet chronically increased metabolic de-
mands for insulin, as occurring under variable states of
insulin resistance. The normal -cell population can adapt
to a sustained stimulation by recruiting -cells into a
higher translational and insulin synthetic activity (2,3) and
possibly by an expansion of its total cell number (4,5). The
molecular mechanisms involved in this chronic adaptation
of the -cell population are not completely understood.
Several reports have highlighted the importance of phos-
phatidylinositol 3-kinase (PI 3-kinase) signaling in -cell
physiology. For example, glucose stimulates the insulin
gene promoter activity via a cascade involving PI 3-kinase.
Indeed, glucose triggers phosphorylation of PDX-1 via the
PI 3-kinase pathway, which induces nuclear translocation
of PDX-1, and the latter then increases insulin gene
transcription (6,7). Furthermore, glucose promotes -cell
survival through the PI 3-kinase/protein kinase B (PKB)
cascade (8). Different actors of the PI 3-kinase cascade
have been identiﬁed as critical control points in insulin
signaling (9), among them 3-phosphoinositide–dependent
protein kinase-1 (PDK1). This kinase was initially recog-
nized by its ability to phosphorylate in the presence of
lipid products generated by PI 3-kinase, the activation loop
of PKB on Thr-308 (10,11). The role of PDK1 in vivo has
been addressed in different organisms by genetic deletion
of PDK1 homologs. In short, knockout studies revealed a
central role of PDK1 in regulation of cell growth and organ
development (12,13). Importantly, PDK1 ablation in -cells
induces diabetes consecutively to a reduction in -cell
mass (14).
The discovery of microRNAs has opened an entirely
new line of thoughts regarding the regulation of signaling
by growth factors and hormones and its perturbations in
situations associated to disease processes. MicroRNAs are
21- to 25-nucleotide–long noncoding RNA molecules ﬁrst
identiﬁed as regulators of the level of several proteins in
Caenorhabditis elegans (15). Currently, hundreds of mi-
croRNAs have been cloned in mammalian species, i.e., 285
in rats, 442 in mice, and 533 in humans. They are collec-
tively annotated and indexed in the microRNA registry
(http://microrna.sanger.ac.uk). Remarkably, some micro-
RNAs are evolutionarily conserved, heralding important
biological functions (16,17). Another feature of several
microRNAs is their time- and tissue-speciﬁc expression,
which points to their role in development and organ
function. Since their discovery in 1993 by Lee et al. (15), a
growing list of pleiotropic effects of microRNAs has ap-
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2708 DIABETES, VOL. 57, OCTOBER 2008peared. Indeed, microRNAs have been shown to regulate
development in C. elegans (18) and metabolism in Dro-
sophila (19). More recently, they have been implicated in
mammals in adipocyte differentiation (20), lipid metabo-
lism (21,22), heart (23) and brain (24) development, and
-cell physiology (25–27).
Here, we were interested in identifying microRNAs
targeting molecules involved in insulin signaling in pancre-
atic -cells. Using computational analysis, we found that
miR-375, previously described as decreasing glucose-in-
duced insulin secretion and characterized by pancreas-
speciﬁc expression pattern (25), targets PDK1, a key
player in the PI 3-kinase cascade. By gain- and loss-of-
function experiments, we found that miR-375 regulates
PDK1 protein level, resulting in modulation of glucose-
stimulatory action on insulin gene expression and DNA
synthesis. We showed that miR-375 interacts directly with
the 3 untranslated region (3UTR) of PDK1 mRNA. Fur-
thermore, exposure of either INS-1E cells or freshly iso-
lated rat islets to glucose modulates endogenous miR-375
precursor levels, suggesting its involvement in regulation
of glucose responsiveness of -cells. Finally, miR-375
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FIG. 1. PDK1 is a target of miR-375. A: Scheme of the interaction between miR-375 and the 3UTR of mouse, rat, and human PDK1. B:
Quantiﬁcation of miR-375 precursor levels. INS-1E cells were transfected with pNeg or pmiR-375 for 48 h. miR-375 precursor was then quantiﬁed
by quantitative RT-PCR. Values for miR-375 precursor were normalized to U6 RNA. C: Analysis of PDK1 protein. INS-1E cells were transfected
as above, and protein extracts were analyzed by Western blot using antibody to PDK1 or to -tubulin. D: Relative quantiﬁcation of PDK1 protein.
Data represent three independent transfections done in triplicate, SE, with n  3. *P < 0.05. E: Relative quantiﬁcation of PDK1 mRNA levels.
RNA extracts were used for quantitative RT-PCR analysis of PDK1 mRNA normalized to 36B4 mRNA. Data represent three independent
transfections done in triplicate, SE, with n  3. F: Study of the interaction between miR-375 and 3UTR of PDK1 mRNA. INS-1E cells were
cotransfected with one of the following pmiR-reporter luciferase vectors (Ambion): empty vector, vector containing the 3UTR PDK-1
oligonucleotide predicted to interact with miR-375, or vector containing a mutated sequence. The cells were also transfected with either pmiR-375
or pNeg. Forty-eight hours after transfection, cells were assayed for luciferase and -galactosidase activity; -galactodidase was used as control
to normalize for transfection efﬁciency. Data represent three independent transfections, each carried out in duplicate, SE, with n  3. *P < 0.05.
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Kakizaki (GK) rats compared with Wistar rats.
RESEARCH DESIGN AND METHODS
Cell culture and transfections. INS-1E -cells were maintained in RPMI
1640 containing 11 mmol/l glucose supplemented with 10% (vol/vol) heat-
inactivated FCS, 100 units/ml penicillin, 100 g/ml streptomycin, 2 mmol/l
L-glutamine, 10 mmol/l HEPES, 1 mmol/l sodium pyruvate, and 50 mol/l
-mercaptoethanol in humidiﬁed 5% (vol/vol) CO2, 95% (vol/vol) air at 37°C
and used between passages 50 and 75. LipofectAMINE 2000 transfection
reagent (Invitrogen, Life Technologies) was used to transfect INS-1E cells. A
total of 3 g pmiR-375 or pNeg and the indicated amounts of 2-O-methyl-
miR-375 or 2-O-methyl-GFP antisense oligonucleotides and 2 l Lipo-
fectAMINE 2000 were used per well with each containing 5  10
5 cells
(six-well plate).
Islet preparation. Islets were isolated by collagenase digestion, elutriation,
and manual handpicking from adult male Wistar rats (150–250 g; Janvier, Le
Genest Saint Isle France). Animals were bred according to Belgian
regulations of animal welfare and used in experiments that were approved
by the local ethical committee. Islets were cultured in Ham’s F10 nutrient
mixture (Gibco, Invitrogen, Carlsbad, CA) supplemented with 0.5% (wt/vol)
BSA (Cohn Analog; Sigma), 2 mmol/l glutamine, 100 units/ml penicillin, 0.1
mg/ml streptomycin, 2% (vol/vol) FCS (Hyclone), and the indicated glucose
concentration.
Generation of DNA constructs. Expression vector driving expression of
miR-375 was prepared by introducing oligonucleotides corresponding to the
murine precursor sequence of mir-375 into pcDNA6.2 (pmiR-375) (Invitrogen).
The oligonucleotide sequences were as follows: sense, 5-TGCTGCCCCGCGAC
GAGCCCC-TCGCACAAACCGGACCTGAGCGTTTTGTTCGTTCGGCTCGCGTG
AGGC-3; and antisense, 5-CCTGGCCTCACGCGAGCCGAACGAACAAAACGCT
CAGGTCCGGTTTGTG CGAGGGGCTCGTCGCGGGGC-3. As negative control,
we used pNeg driving the expression of an unrelated known microRNA precursor
(Invitrogen). The rat PDK1 3UTR target site was cloned using the following
oligonucleotides: sense, 5-ACCCAACCACACAAAGAACAAAA-3; and antisense,
5-TTTTGTTCTTTGTGTGGTTGGGT-3 in the 3UTR of the Renilla luciferase
reporter vector, pmiR-Report luciferase (Ambion), as described previously (28).
As a negative control response element, we used a mutated sequence by inserting
the following oligonucleotides: sense, 5-ACCCAACCACACCCCTCCTGGGG-3;
and antisense, 5-CCCCAGGAGGGGTGTGGTT-GGGT-3. Loss of function exper-
iments were carried out using the following: 2-O-methyl-375, UGCAUCACGCG
AGCCGAACGAACAAAUAAGL, and 2-O-methyl-eGFP, AAGGCAAGCUGACCC
UGAAGUL.
Luciferase assays. INS-1E cells were cultured in six-well plates and transfected
with different reporter vectors (p-Luc-Empty, p-Luc 3UTR PDK1 or p-Luc-3UTR
MUT PDK1) and cotransfected with pNeg or pmiR-375. Cells were assayed 48 h
after transfection with the dual-luciferase reporter assay system (Promega,
Madison, WI). Luciferase activity was normalized by -galactosidase activity.
RNA RT-PCR and real-time PCR. RNA from transfected -cells and rat
islets was isolated using TRIzol reagent (Invitrogen), and its quality was
veriﬁed by Agilent Bioanalyzer (minimal cutoff RNA integrity number 8).
From each transfected well, 1 g total RNA was reverse-transcribed. For
microRNAs precursor detection, RT was performed as described (29). Mi-
croRNA precursor primer sequences are described by Jiang et al. (30). The
following forward and reverse primers were used for ampliﬁcation: PDK1,
5-CCCACGTGATGGACTCAAAGA-3 (reverse) and 5-AAGGGTACGGGCCTC
TCAAA-3 (forward); Insulin-1, 5-GTGCACCAACAGGGCCAT-3 (reverse)
and 5-CAGAGACCATCAGCAAGCAGG-3 (forward); U6, 5-AACGCTTCACG
AATTTGCGT-3 (reverse) and 5-CTCGCTTCGGCAGCACA-3 (forward); and
36B4, 5-ATGATCAGCCCGAAGGAGAAGG-3 (reverse) and 5-CCACGAAAA
TCTCCAGAGGCAC-3 (forward).
Analysis of total cell extracts and Western blotting. Two days after
transfection, INS-1E cells were washed with ice-cold PBS and processed for
protein isolation. For Western blotting, total proteins were separated by
electrophoresis and transferred to polyvinylidene diﬂuoride membranes (Im-
mobilon-P; Millipore, Bedford, MA) followed by blotting. Immunodetection
was performed using afﬁnity-puriﬁed polyclonal antibodies to PDK1 and
phospho–glycogen synthase kinase (GSK)3 (Cell Signaling, Beverly, MA) and
to phospho-Thr-308 PKB, total PKB, or total GSK3 (Santa Cruz Biotechnology,
Santa Cruz, CA). To assess the total protein amount, membranes were
stripped and reprobed with antibody to -tubulin (Sigma-Aldrich, St. Quentin-
Fallavier, France).
Cell viability assay. Cells (2  10
5 per well) seeded in 12-well plastic plates
were transfected with pmiR-375 or pNeg and incubated at 37°C. After 48 h, cell
viability was assessed by the ability of metabolically active cells to reduce
tetrazolium salt to orange-colored formazan compounds. The absorbance of
the samples was measured with a spectrophotometer reader (wavelength 450
nm). Data shown correspond to mean values from three independent exper-
iments measured in sextuplicate.
Measurement of DNA synthesis using [methyl-
3H]thymidine incorpora-
tion. Cells were plated in six-well plates at a density of 5  10
5 cells per well.
After reaching 60% conﬂuence, they were transfected with pmiR-375 or pNeg.
Twenty-four hours later, cells were starved in RPMI containing 0.5% FCS
(vol/vol) for 24 h and then replaced in RPMI 10% (vol/vol) FCS. After 24 h,
DNA synthesis was assayed by adding 1 Ci [methyl-
3H]thymidine/well and by
incubating the cells for another 2 h. Then cells were washed twice with PBS,
ﬁxed with 10% (vol/vol) trichloroacetic acid for 30 min, and solubilized by
adding 300 l 0.2 N NaOH to each well. Radioactivity, reﬂecting incorporation
of [methyl-
3H]thymidine into DNA, was measured by adding scintillation
liquid and counting.
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FIG. 2. Effect of miR-375 on PKB and GSK3 phosphorylation. A:
Analysis of Thr-308-phosphorylation of PKB. INS-1E cells were trans-
fected with pNeg or pmiR-375. Forty-eight hours later, cells were
starved in Krebs-Ringer bicarbonate HEPES medium for 2 h and either
were or were not stimulated with 100 nmol/l insulin for 5 min. Protein
extracts were analyzed by Western blot using antibody to phos-
pho308Thr PKB and total PKB. B: Quantiﬁcation of Thr-308-phosphor-
ylated PKB. C: Analysis of GSK3 phosphorylation. Protein extracts
were analyzed by Western blot using antibody to phosphoGSK3 and
total GSK3. D: Quantiﬁcation of phosphorylated GSK3. The data
presented correspond to three independent experiments, each done in
duplicate, SE, with n  3. *P < 0.05.
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miR-375 regulates PDK1 protein level. To identify
potential targets of miR-375, we used computational algo-
rithms designed to predict mRNA targets of microRNAs.
One of the predicted targets for miR-375 is PDK1. The
predicted miR-375 binding site in the 3UTR of PDK1
mRNA (Fig. 1A) appears to be phylogenetically main-
tained. This would suggest that the function of miR-375 as
potential regulator of PDK1 has been conserved in mice,
rats, and humans. To investigate whether miR-375 affects
PDK1, plasmids driving the expression of miR-375 precur-
sor (pmiR-375) or control (pNeg) were transfected in
INS-1E cells. pmiR-375 increased miR-375 precursor levels
by 500-fold, as assayed by real-time PCR (Fig. 1B).
Functional analysis shows that miR-375 precursor overex-
pression in INS-1E cells results in a reduction of 40% of
PDK1 protein (Fig. 1C and D) without affecting its mRNA
level (Fig. 1E), indicating that miR-375 acts as a transla-
tional repressor. To evaluate whether the predicted miR-
375 target site in the 3UTR of PDK1 mRNA was directly
involved in miR-375–induced reduction in PDK1 protein,
we cloned the putative 3UTR target site downstream of a
luciferase reporter gene and cotransfected this p-Luc-
3UTR PDK1 construct into INS-1E cells with pmiR-375 or
pNeg. Luciferase activity of cells transfected with pmiR-
375 and p-Luc-3UTR PDK1 was decreased by 25%
compared with cells cotransfected with control pNeg and
p-Luc-3UTR PDK1 (Fig. 1F). With negative control con-
structs p-Luc-Empty and p-Luc-3UTR MUT PDK1, no
reduced luciferase activity was observed when cells were
cotransfected with pmiR-375 compared with pNeg. Taken
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FIG. 3. Effect of miR-375 on glucose-enhanced insulin gene expression
and cell proliferation. A: Quantiﬁcation of insulin mRNA. INS-1E cells
were transfected as above. Forty-eight hours later, cells were starved
in RPMI 1640 with 0.5% (vol/vol) FCS containing 2 mmol/l glucose for
16 h and treated with 2 or 20 mmol/l glucose for 1 h. Insulin mRNA
expression was analyzed by quantitative RT-PCR and normalized to
36B4 transcript. Data represent ﬁve independent experiments carried
out in triplicate, SE, with n  5. *P < 0.05, **P < 0.005. B:
Measurement of [methyl-
3H]thymidine incorporation. INS-1E cells
were transfected as above. Twenty-four hours later, cells were starved
in RPMI 1640 with 0.5% (vol/vol) FCS containing 2 mmol/l glucose for
16 h and treated with 2 or 20 mmol/l glucose for 24 h, and cell
proliferation was assessed by measuring [methyl-
3H]thymidine incor-
poration. Data represent three independent experiments done in
triplicate, SE, with n  3. *P < 0.05.
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FIG. 4. Effect of miR-375 on cell number, viability, and proliferation. A:
Cell number counting. INS-1E cells were seeded in six-well plates (5 
10
5/well) and transfected with pNeg or premiR-375. Cells were starved
in RPMI 1640 containing 0.5% (vol/vol) FCS and 11 mmol/l glucose for
24 h and then replaced in RPMI 1640 10% (vol/vol) FCS and 11 mmol/l
glucose for 24 h. Cells were counted using Coulter counter. B: Cell
viability assay. INS-1E cells were seeded in 12-well plates (2 
10
5/well) and transfected as above. Forty-eight hours later, cell viabil-
ity was assessed as described in RESEARCH DESIGN AND METHODS. Data
represent three independent transfections done in sextuplicate, SE,
with n  3. *P < 0.05. C: Measurement of [methyl-
3H]thymidine
incorporation. Cells were seeded in six-well plates (5  10
5/well) and
treated as in A. Cell proliferation was assessed by measuring [methyl-
3H]thymidine incorporation. Data represent three independent exper-
iments, each run in triplicate, SE, with n  3. *P < 0.05.
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miR-375 and PDK1 mRNA.
miR-375 decreases insulin signaling downstream of
PDK1. The PI 3-kinase/PDK1/PKB signaling pathway is
used by insulin in pancreatic -cells to elicit several
actions of the hormone. It is generally believed that after
insulin stimulation of cells, PDK1 is recruited to the
plasma membrane and phosphorylates PKB on Thr-308,
which becomes activated and phosphorylates a series of
substrates, including GSK3/. Downregulation of PDK1
in -cells is expected to cause a decrease in insulin-
induced signaling dependent on this particular enzyme. To
study the effect of miR-375 on insulin signaling, we exam-
ined the phosphorylation state of molecules functioning
downstream of PDK1. Immunoblot analysis showed that in
response to insulin, PKB phosphorylation on Thr-308 is
less abundant in cells overexpressing miR-375 precursor
compared with control cells (Fig. 2A and B). Consistent
with this latter observation, ectopic expression of miR-375
precursor also reduces insulin-induced phosphorylation of
GSK3 (Fig. 2C and D).
miR-375 decreases glucose-induced insulin gene
expression and DNA synthesis. Because PI 3-kinase
signaling has been implicated in glucose-induced upregu-
lation of insulin gene expression and because we found
that miR-375 decreases PDK1 protein, we examined the
impact of miR-375 on insulin gene expression in response
to glucose in INS-1E cells. We found that, as expected,
high glucose concentration (20 mmol/l) induced insulin
gene expression in control cells, but this effect was lost in
cells overexpressing pre-miR-375 (Fig. 3A). To test
whether PDK1 is involved in the glucose-induced increase
in cell proliferative activity, we analyzed the impact of
miR-375 on cellular [methyl-
3H]thymidine incorporation.
As illustrated in Fig. 3B, the stimulatory effect of glucose
on DNA synthesis was reduced by 50% when miR-375
precursor was overexpressed.
miR-375 attenuates cell viability and proliferation.
Because the PI 3-kinase/PKB cascade has been involved in
cell survival and proliferation, we investigated the conse-
quences of miR-375 expression on cell viability and prolif-
eration. Thus, INS-1E cells were transfected with pmiR-
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with n  3. **P < 0.01. C: Quantiﬁcation of insulin mRNA level. INS-1E cells were transfected with either 2-O-methyl-GFP or 2-O-methyl-miR-375
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***P < 0.001.
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2712 DIABETES, VOL. 57, OCTOBER 2008375 or pNeg, and 48 h after transfection, cell number and
viability were measured. We found that miR-375 overex-
pression reduced cell number by 25% (Fig. 4A) and cell
viability by 20% (Fig. 4B). To further determine the
effects of miR-375 on cell proliferation, DNA synthesis was
measured using [methyl-
3H]thymidine incorporation. As
shown in Fig. 4C, transfection with miR-375 precursor
inhibited INS-1E cell proliferative activity by 20% com-
pared with control cells.
2-O-methyl-miR-375 increases PDK1 protein level
and glucose-stimulatory action on insulin mRNA and
DNA synthesis. Because miR-375 targets PDK1 and im-
pairs glucose-stimulated insulin gene expression and cell
proliferation, we investigated whether antisense oligonu-
cleotides of miR-375 induce effects opposite to those seen
after miR-375 overexpression. Using 2-O-methyl-miR-375
antisense oligonucleotides, we found that blocking miR-
375 augments PDK1 protein. This increase reaches 40%
when cells are transfected with either 250 or 500 nmol/l
2-O-methyl-miR-375 (Fig. 5A and B). Importantly, we
found that 2-O-methyl-miR-375–induced miR-375 deple-
tion increases both basal and glucose-enhanced insulin
mRNA (Fig. 5C). Finally, as shown in (Fig. 5D), 2-O-
methyl-miR-375 increases the glucose stimulatory ac-
tion on [
3H]thymidine incorporation compared with
2-O-methyl-GFP.
Glucose speciﬁcally decreases miR-375 expression.
To investigate whether glucose-induced responses in
INS-1E cells could be mediated by microRNAs, we ana-
lyzed the expression of a series of microRNAs in cells
maintained for 4 days with different glucose concentra-
tions. Using quantitative RT-PCR as described previously
(29), we found that miR-375 precursor is negatively regu-
lated by glucose. Indeed, 11 and 22 mmol/l glucose induce
a decrease of 60 and 70%, respectively, in miR-375
precursor levels compared with 5.5 mmol/l glucose (Fig.
6A). To look at whether this glucose effect was limited to
miR-375, we measured the level of three other microRNAs
expressed in INS-1E cells. In contrast to miR-375, both
miR-296 and miR-9 are positively regulated by prolonged
glucose treatment. Indeed, glucose leads to a concentra-
tion-dependent increase in miR-296 precursor (Fig. 6B),
whereas miR-9 precursor is robustly increased after cell
exposure to 11 mmol/l glucose. At higher glucose concen-
tration, miR-9 expression tends to decline but remains
higher compared with low glucose (5.5 mmol/l) condition
(Fig. 6C). Finally, miR-122, which presents a speciﬁc liver
expression, is detected in INS-1E cells, but glucose does
not modulate its expression (Fig. 6D).
The levels of miR-375 and PDK1 are inversely corre-
lated in glucose-stimulated INS-1E cells. To further
document the role of miR-375, we analyzed the expression
of premiR-375 in INS-1E cells treated for 1 or 24 h with 2
or 20 mmol/l glucose. We found that glucose induces a
robust decrease in miR-375 after 1 and 24 h (Fig. 7A and
B). Furthermore, immunoblot analyses show that PDK1
protein level is slightly, but not signiﬁcantly, increased
within1ho fglucose treatment (Fig. 7C). Remarkably, in
INS-1E cells exposed for 24 h to 20 mmol/l glucose, PDK1
protein is increased (fourfold), and its level thus inversely
correlates with that of miR-375 (Fig. 7D). Finally, de-
creased miR-375 without change in PDK1 level seen after
1 h of glucose treatment occurs with enhanced insulin
gene expression (Fig. 7E). Decreased miR-375 and in-
creased PDK1 levels are associated with enhanced DNA
synthesis as reﬂected by increased thymidine incorpora-
tion seen within 24 h of glucose treatment (Fig. 7F).
Glucose regulates miR-375 expression in freshly iso-
lated rat pancreatic islets. To characterize the glucose-
mediated miR-375 regulation, we analyzed the expression
level of miR-375 precursor in isolated rat islets that had
been exposed to 5, 10, or 20 mmol/l glucose for 2- or 72-h
periods, which represent conditions in which the acute
and chronic inﬂuences, respectively, of glucose can be
studied. After2ha tstimulatory glucose concentrations
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FIG. 6. Expression of microRNAs in glucose-stimulated INS-1E cells.
INS-1E cells were cultured in six-well plates (5  10
5/well) and starved
in RPMI 1640 with 0.5% (vol/vol) FCS containing 2 mmol/l glucose for
24 h and thereafter treated with 5.5, 11, or 22 mmol/l glucose for 4 days.
RNA extracts were reverse-transcribed and analyzed by RT-PCR for
the expression of miR-375 (A), miR-296 (B), miR-9 (C), and miR-122
(D) precursors. Expression levels of microRNA precursors were nor-
malized to U6 transcript. Data represent three independent experi-
ments each done in duplicate, SE, with n  3. *P < 0.05, **P < 0.005.
Results were expressed relative to the low glucose condition (5.5
mmol/l Glc).
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DIABETES, VOL. 57, OCTOBER 2008 2713(10 or 20 mmol/l), miR-375 expression is lower than in the
basal 5 mmol/l condition (Fig. 8A). After 72 h, a lower
expression level was measured at 5 mmol/l than at 10 and
20 mmol/l, whereas the level at 20 mmol/l tended to be
lower than at 10 mmol/l (Fig. 8B).
Reduced miR-375 expression in freshly isolated islets
from diabetic GK rats. To study miR-375 expression
under in vivo conditions of hyperglycemia, we analyzed
islets from diabetic GK rats. We found that miR-375 is
downregulated in diabetic GK rats compared with control
Wistar rats (Fig. 8C). Furthermore, in GK rats, this de-
crease in miR-375 expression is associated with a modest,
albeit not signiﬁcant, increase in insulin mRNA level (Fig.
8E). Finally, the expression of miR-124a2, which has been
involved in insulin mRNA expression (27), is upregulated
in GK rats (Fig. 8D).
DISCUSSION
During recent years, microRNAs have emerged as impor-
tant regulators of cell fate and metabolism. Although
several microRNAs have been implicated in a variety of
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FIG. 7. Effect of glucose on endogenous miR-375 and PDK1 expression in INS-1E cells. INS-1E cells were cultured in six-well plates (5  10
5/well)
and starved in RPMI 1640 with 0.5% (vol/vol) FCS containing 2 mmol/l glucose for 24 h and thereafter treated with 2 or 20 mmol/l glucose for 1 h
(A)o r2 4h( B). RNA extracts were analyzed for miR-375 precursor. Expression of miR-375 precursor was normalized to the U6 transcript level.
Protein extracts from cells stimulated for1h( C)o r2 4h( D) with 2 or 20 mmol/l glucose were analyzed by Western blot using antibody to PDK1
or to -tubulin. INS-1E cells were starved in RPMI 1640 with 0.5% (vol/vol) FCS containing 2 mmol/l glucose for 16 h and treated with 2 or 20
mmol/l glucose for1h( E)o r2 4h( F). Cell proliferation was assessed by measuring [methyl-
3H]thymidine incorporation. Data represent three
independent experiments done in triplicate, SE, with n  3. *P < 0.05, **P < 0.005.
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2714 DIABETES, VOL. 57, OCTOBER 2008disease processes (31), only a few have been linked to
insulin signaling and diabetes (32). Using either a gain- or
loss-of-function approach, we show here in a pancreatic
-cell line that miR-375, previously described to reduce
glucose-induced insulin secretion by inhibiting Mtpn pro-
tein (25), is able to downregulate PDK1 protein by inter-
fering directly with its mRNA. By targeting PDK1, a key
player in the PI 3-kinase signaling cascade, miR-375 de-
creases insulin-induced phosphorylation of PKB and
GSK3, both acting downstream of PDK1.
It is interesting to mention that pancreatic -cell speciﬁc
PDK1 knockout in mice results in a reduced number and
size of -cells, and in decreased islet density (14). These
data and ours are intriguing in the context of a report
showing that miR-375 knockout by morpholinos in ze-
braﬁsh embryos leads to defects in the development of
pancreatic islets (33).
Previous studies have shown that inhibition of the PI
3-kinase cascade dampens glucose-induced insulin gene
expression (6). To document the biological role of miR-375
as an inhibitor of PI 3-kinase signaling downstream of
PDK1, we analyzed the effect of miR-375 overexpression
or depletion on glucose-induced insulin gene expression.
Our ﬁndings that miR-375 controls insulin gene expression
stimulated by glucose are consistent with the notion that
the PI 3-kinase cascade is important for glucose stimula-
tory action on insulin gene expression. A chief observation
of our study is that microRNA expression seems to be
glucose sensitive. Importantly, the increased insulin gene
expression seen in INS-1E cells exposed to high glucose is
associated with reduced expression of miR-375 precursor.
Our in silico analysis (data not shown) reveals that miR-
375 is located in an intergenic region between cryba2 and
Ccdc108 genes on the mouse chromosome 1. Comparison
of genomic sequences (http://ecrbrowser.decode.org/)
across humans, mice, and rats shows that a 5-kb genomic
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DIABETES, VOL. 57, OCTOBER 2008 2715region downstream of the miR-375 precursor contains
highly conserved elements. Moreover, according to a
recent publication, several regions located downstream
and upstream of the miR-375 gene interact with NeuroD1/
BETA2 and PDX-1 (34). Taken together, these facts sug-
gest that the gene encoding for miR-375 may behave as a
locus controlled by its own promoter.
Although glucose decreased miR-375 expression within
1 h in INS-1E cells, a longer exposure time was needed to
observe the downstream stimulatory effect on PDK1 pro-
tein expression. This suggests that miR-375 suppresses
synthesis of PDK1 protein. Interestingly, prolonged glu-
cose exposure of INS-1E cells (35) has been shown to
increase insulin receptor substrate 2 gene expression,
protein localization to the plasma membrane, and PKB
phosphorylation. These observations together with ours
indicate that in INS-1E cells, glucose induces a decrease in
miR-375 followed by an increase in PDK1 protein and an
activation of the PI 3-kinase cascade and, hence, -cell
proliferation.
Glucose was also found to regulate miR-375 expression
in primary islet tissue. A 2-h incubation was used to
measure levels in freshly isolated rat islets at glucose
concentrations known to have exerted dose-dependent
stimulations of their metabolic, secretory, and protein
biosynthetic activities. We found miR-375 expression to be
lower at 10 and 20 mmol/l than at 5 mmol/l glucose, which
is similar to the effect seen in INS-1E cells. The 72-h
culture condition compares expression in islets that have
maintained this functional responsiveness (10 and 20
mmol/l glucose during culture) with that in islets having
lost this responsiveness and showing increased suscepti-
bility to apoptosis (5 mmol/l glucose during culture)
(36–38). Expression of miR-375 is lower in islets showing
viability consequences of prolonged glucose deprivation; it
is unknown whether this reduction participates in the
apoptotic pathway and can be interpreted in light of a
report showing that miR-375 knockout by morpholinos in
zebraﬁsh leads to defects in islet development (33). When
comparing functionally competent islets cultured at con-
trol (10 mmol/l) versus elevated (20 mmol/l) glucose
concentrations, miR-375 levels appeared lower after pro-
longed glucose hyperactivation (20 mmol/l). Islets isolated
from diabetic GK rats exhibited a lower miR-375 expres-
sion than islets from Wistar rats, which can be considered
as further evidence for the suppressing effect of supra-
physiological glucose concentrations. Such reduced miR-
375 level is expected to be associated with increased
insulin mRNA, but this was not the case in GK rats,
suggesting a possible failure of the PDK1/PKB cascade to
increase insulin gene expression. On the other hand,
expression of miR-124a2, previously described as inhibit-
ing insulin gene expression (27), is upregulated in GK
islets. Hence, we speculate that the antagonizing actions of
miR-124a2 and miR-375 are counterbalanced, resulting in
an unchanged insulin mRNA level in GK islets. An alter-
native explanation is that the lower expression in GK islets
results from a prolonged intracellular deprivation of glu-
cose signals, as in the case of the islets cultured in 5
mmol/l glucose for 72 h that progress to apoptosis.
According to recent studies (39,40), total -cell mass is
reduced in patients and animals with type 2 diabetes and
contributes to the disease process. Notably, -cell–speciﬁc
PDK1 knockout in mice leads to diabetes as a result of a
reduction in -cell mass (14). Another in vitro study
reported that decreased PDK1 in human glioblastoma cells
obtained with antisense oligonucleotides or with RNA
interference blocks cell proliferation (41). Here, we ﬁnd
that miR-375 downregulates PDK1 by directly targeting
PDK1 mRNA and may therefore impact on cell prolifera-
tion given its key role in the PI 3-kinase/PKB cascade. In
this context, several studies have revealed dysregulations
in microRNA expression in human cancers (42), suggest-
ing that microRNAs may act on cell proliferation. More
directly related to our work, recent studies show that
miR-375 is decreased in pancreatic cancer (43–45). Our
results point to a similar antiproliferative action of miR-
375, because we found that miR-375 attenuates cell viabil-
ity and proliferation.
A ﬁrst key ﬁnding of our work is that miR-375 is
regulated by glucose, which is the central molecule in islet
metabolism and physiology. A second important observa-
tion is that miR-375 inhibits glucose-induced INS-1E cell
proliferation. This result is particularly interesting in the
context of diabetes. Although a distinct disease process is
responsible for type 1 and type 2 diabetes, in both cases,
-cell failure occurs. Developing new approaches to in-
duce -cells to replicate is a supereminent goal in diabetes
research. Our data presented here reveal the pancreatic
islet-speciﬁc microRNA, miR-375, as an important regula-
tor of glucose-stimulated insulin gene expression and
proliferation of pancreatic -cells. Taking into account the
fact that miR-375 also decreases insulin secretion (25),
miR-375 emerges as a target that should be prioritized to
enhance islet function and to combat -cell failure.
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